BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, eligible for PEA-PME equity savings plans) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its participation in two symposiums marking World Down Syndrome Day. The 18th World Down Syndrome Day Colloquium (Bourg-en-Bresse, France, March 17-19, 2023) Pier Vincenzo Piazza, CEO of Aelis Farma, spoke on March 1
Source link
